| Literature DB >> 34471936 |
Alkan Bayrak1, Altuğ Duramaz2, Başar Burak Çakmur2, Cemal Kural3, Serdar Hakan Basaran3, Ersin Erçin3, Alev Kural3, Hüseyin Tamer Ursavaş4.
Abstract
PURPOSE: To evaluate the effect of COVID-19 positivity on inflammatory parameters and 30-day mortality rates in patients over 65 years of age who were operated on for intertrochanteric femur fractures (IFF).Entities:
Keywords: COVID-19; Inflammation; Intertrochanteric femur fracture; Mortality
Mesh:
Year: 2021 PMID: 34471936 PMCID: PMC8409697 DOI: 10.1007/s00264-021-05201-3
Source DB: PubMed Journal: Int Orthop ISSN: 0341-2695 Impact factor: 3.075
Demographic features of patients
| Age (year) | 79.0 ± 12.4 | 79.5 ± 14.9 | ||
| Gender | Male | 22 (34.9) | 9 (37.5) | |
| Female | 41 (65.1) | 15 (62.5) | ||
| Operation duration (min) | 64.0 ± 9.7 | 67.5 ± 11.1 | ||
| Time to surgery (hours) | 28 (24–36) | 34 (31–52) | ||
| Hospitalization period (day) | 9 (7–11) | 11 (8.5–15.5) | ||
| Femur head-neck angle | 11.3 ± 1.7 | 11.6 ± 2.1 | ||
| SII index | 1728.8 + 1195.8 | 1578.5 + 765.1 | 0.45 | |
| ASA | I | 1 (1.6) | 0 (0) | |
| II | 16 (25.4) | 4 (16.7) | ||
| III | 46 (73) | 20 (83.3) | ||
| Fracture type | A01.1 | 3 (4.8) | 0 (0) | |
| A01.2 | 7 (11.1) | 1 (4.2) | ||
| A01.3 | 2 (3.2) | 0 (0) | ||
| A02.1 | 16 (25.4) | 5 (20.8) | ||
| A02.2 | 11 (17.5) | 10 (41.7) | ||
| A02.3 | 12 (19) | 2 (8.3) | ||
| A03.1 | 3 (4.8) | 4 (16.7) | ||
| A03.3 | 9 (14.3) | 1 (4.2) | ||
| A2.2 | 0 (0) | 1 (4.2) | ||
| PCR | Negative | 63 (100) | 11 (45.8) | |
| Positive | 0 (0) | 13 (54.2) | ||
| Chest CT | Negative | 63 (100) | 2 (8.3) | |
| Positive | 0 (0) | 22 (91.7) | ||
| Treatment | No | 63 (100) | 4 (16.7) | |
| Yes | 0 (0) | 20 (83.3) | ||
| Comorbidity | No | 20 (31.7) | 6 (25) | |
| Hipertension | 15 (23.8) | 5 (20.8) | ||
| Diabetes mellitus | 19 (30.2) | 6 (25) | ||
| Others (stroke, chronic renal failure, etc.) | 9 (14.3) | 7 (29.2) |
aStudent’s t test
bPearson’s chi-square test
cMann-Whitney’s U test
dFisher-Freeman-Halton’s test
*p < 0.05
Evaluation of mortality rate, ICU referral rate, and blood transfusion rate between the COVID-19 positive and COVID-19 negative patients
| COVID ( −) | COVID ( +) | |||
|---|---|---|---|---|
| Blood transfusion | No | 29 (46.0) | 5 (20.8) | |
| Yes | 34 (54.0) | 19 (79.2) | ||
| ICU referral | No | 60 (95.2) | 18 (75) | |
| Yes | 3 (4.8) | 6 (25) | ||
| Exitus | No | 61 (96.8) | 19 (79.2) | |
| Yes | 2 (3.2) | 5 (20.8) | ||
bPearson’s chi-square test
gFisher’s exact test
*p < 0.05, **p < 0.01
Evaluation of biochemical analysis between the COVID-19 positive and COVID-19 negative patients
| Preoperative Hb (gr/dl) | 11.3 ± 1.7 | 11.6 ± 2.1 | ||
| Postoperative Hb (gr/dl) | 10.0 ± 1.5 | 9.7 ± 1.6 | ||
| Preoperative Neutrophil/lymphocyte ratio (10e3/uL) | 6.7 (4.8–10.5) | 7.7 (3–11.5) | ||
| Postoperative Neutrophil/lymphocyte ratio (10e3/uL) | 8 (4.5–10.7) | 11.6 (7–17.1) | ||
| Preoperative LDH (U/L) | 223 (161–269) | 290 (207–352.5) | ||
| Postoperative LDH (U/L) | 215 (165–282) | 258.5 (205.5–338) | ||
| Preoperative urea (mg/dl) | 48 (36–73) | 48 (39–68.5) | ||
| Postoperative urea (mg/dl) | 59 (38–80) | 60 (35–92.5) | ||
| Preoperative AST/ALT (U/L) | 1.8 ± 0.6 | 1.7 ± 0.7 | ||
| Postoperative AST/ALT (U/L) | 2.5 ± 1.4 | 2.5 ± 1.7 | ||
| Preoperative LDL (mg/dl) | 128 (97–150) | 125 (111–172) | ||
| Postoperative LDL (mg/dl) | 124 (92–150) | 125.5 (88–172.5) | ||
| Preoperative D-Dimer (ug/L) | 1.2 (0.5–2.5) | 2 (1.2–3.4) | ||
| Postoperative D-Dimer (ug/L) | 1.1 (0.4–2.1) | 2.2 (1.2–3.4) | ||
| Preoperative T-Prot/Alb (g/L) | 1.81 ± 0.18 | 1.80 ± 0.19 | ||
| Postoperative T-Prot/Alb (g/L) | 1.86 ± 0.20 | 1.94 ± 0.17 | ||
| Preoperative CRP (mg/dl) | 9 (3–36) | 6 (2–56.5) | ||
| Postoperative CRP (mg/dl) | 27 (11–81) | 149.5 (97–245.5) | ||
| Preoperative ESR (mm/h) | 11 (6–14) | 24.5 (15–28) | ||
| Postoperative ESR (mm/h) | 15 (8–19) | 29.5 (23–38) | ||
| Preoperative PCT (ng/mL) | 0.1 (0.1–0.2) | 0.1 (0.1–0.3) | ||
| Postoperative PCT (ng/mL) | 0.1 (0.1–0.3) | 0.2 (0.1–0.5) | ||
| Ferritin (pre-treatment) µg/L | 148 (89–195) | 161.5 (63–265) | ||
| Ferritin (post-treatment) µg/L | 170 (90–200) | 277.5 (132.5–361.5) | ||
Abbreviations: Hb hemeglobin, LDH lactate dehydrogenase, AST aspartateaminotransferase, ALT alanine aminotransferase, LDL low density lipoprotein
aStudent’s t test
cMann-Whitney’s U test
ePaired samples test
fWilcoxon’s signed-ranks test
*p < 0.05, **p < 0.01